PharmaMar SA Reports Robust Revenue Growth in 2024
Company Announcements

PharmaMar SA Reports Robust Revenue Growth in 2024

Pharma Mar SA (ES:PHM) has released an update.

PharmaMar SA has reported an 8% increase in total revenue to €126.5 million as of September 30, 2024, with net profit rising to €7.4 million. The company’s earnings have been bolstered by a 10% growth in royalties, particularly from its partnership with Jazz Pharmaceuticals, and a significant increase in non-recurring revenue from license agreements. Despite a slight dip in oncology sales, strong R&D investments and strategic partnerships are driving PharmaMar’s financial performance.

For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Spain Auto-Generated NewsdeskPharma Mar S.A. Announces Strategic Share Capital Reduction
TipRanks Spain Auto-Generated NewsdeskPharma Mar Announces Positive Trial Results for Cancer Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App